Indian Firms Grow: Puravankara, Glenmark, TCS Expand
By Sivam
Discover how Indian giants Puravankara, Glenmark Pharma, and TCS are expanding their reach through strategic land acquisition, new drug launches, and major partnerships.
Indian Firms Announce Key Expansions
Three major Indian firms are making significant moves: Puravankara strengthens its presence in Bengaluru with a land acquisition, Glenmark Pharmaceuticals unveils a new injection in the US, and Tata Consultancy Services (TCS) seals a multi-year partnership with Tottenham Hotspur.
Puravankara’s Bengaluru Land Grab
Puravankara has acquired a 9.73-acre land parcel in Sanna Ammanikere, North Bengaluru. This move reinforces its strategy in high-growth micro-markets.
- The acquisition has a development potential of approximately 0.89 million sq ft.
- It holds an estimated gross development value (GDV) of Rs 800 crore.
- The upcoming residential development aims to meet demand for well-designed homes in connected urban areas.
Glenmark Pharma Launches New Injection
Glenmark Pharmaceuticals Inc., USA, a wholly-owned subsidiary, has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial.
- The injection is bioequivalent and therapeutically equivalent to ProvayBlue Injection.
- ProvayBlue recorded annual sales of around $19.0 million for the 12-month period ending April 2026, according to IQVIA data.
TCS Partners with Tottenham Hotspur
Tata Consultancy Services (TCS) announced a multi-year strategic partnership with Tottenham Hotspur Football Club. TCS will serve as the Club’s Digital Transformation Partner.
- TCS will deploy its expertise in Salesforce and Cybersecurity.
- The partnership aims to enhance Tottenham Hotspur’s digital operations.
- It will also drive deeper fan engagement and leverage advanced analytics and insights.